• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    1/4/24 4:31:07 PM ET
    $ALLO
    $APLT
    $ATXI
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLO alert in real time by email

    Gainers

    • Dermata Therapeutics (NASDAQ:DRMA) stock increased by 113.1% to $1.3 during Thursday's after-market session. The market value of their outstanding shares is at $4.6 million.
    • Intelligent Bio Solutions (NASDAQ:INBS) shares increased by 19.17% to $0.36. The market value of their outstanding shares is at $3.1 million.
    • Exagen (NASDAQ:XGN) shares increased by 15.33% to $2.18. The market value of their outstanding shares is at $37.1 million.
    • Nemaura Medical (NASDAQ:NMRD) shares increased by 12.53% to $0.12. The market value of their outstanding shares is at $3.4 million.
    • Inspire Veterinary (NASDAQ:IVP) shares increased by 9.85% to $0.38. The market value of their outstanding shares is at $3.3 million.
    • MyMD Pharmaceuticals (NASDAQ:MYMD) stock increased by 9.52% to $0.23. The market value of their outstanding shares is at $11.7 million.

    Losers

    • Applied Therapeutics (NASDAQ:APLT) stock declined by 36.9% to $2.39 during Thursday's after-market session. The market value of their outstanding shares is at $184.5 million.
    • Voyager Therapeutics (NASDAQ:VYGR) stock declined by 10.07% to $9.74. The company's market cap stands at $428.5 million.
    • Avenue Therapeutics (NASDAQ:ATXI) stock decreased by 9.59% to $0.31. The market value of their outstanding shares is at $4.1 million.
    • Alaunos Therapeutics (NASDAQ:TCRT) shares decreased by 7.72% to $0.12. The company's market cap stands at $28.2 million.
    • Cognition Therapeutics (NASDAQ:CGTX) stock decreased by 6.99% to $1.85. The market value of their outstanding shares is at $59.4 million.
    • Allogene Therapeutics (NASDAQ:ALLO) stock decreased by 6.49% to $3.17. The market value of their outstanding shares is at $533.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLO
    $APLT
    $ATXI
    $CGTX

    CompanyDatePrice TargetRatingAnalyst
    Allogene Therapeutics Inc.
    $ALLO
    1/9/2026$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Applied Therapeutics Inc.
    $APLT
    12/12/2025Outperform → Neutral
    Robert W. Baird
    Applied Therapeutics Inc.
    $APLT
    12/3/2025$1.00Outperform → Market Perform
    Leerink Partners
    Allogene Therapeutics Inc.
    $ALLO
    10/10/2025Neutral → Underweight
    Analyst
    Exagen Inc.
    $XGN
    9/11/2025$15.00Buy
    B. Riley Securities
    Exagen Inc.
    $XGN
    7/30/2025$12.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Exagen Inc.
    $XGN
    7/23/2025$12.00Buy
    Craig Hallum
    Allogene Therapeutics Inc.
    $ALLO
    5/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    More analyst ratings

    $ALLO
    $APLT
    $ATXI
    $CGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    3/17/26 5:44:21 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Ricciardi Lisa covered exercise/tax liability with 28,960 shares, was granted 631,300 shares and bought $30,001 worth of shares (38,851 units at $0.77), increasing direct ownership by 207% to 893,685 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    2/4/25 4:11:53 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Black Jeffrey G. bought $66,448 worth of shares (22,298 units at $2.98), increasing direct ownership by 9% to 274,492 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    11/19/24 7:24:38 PM ET
    $XGN
    Medical Specialities
    Health Care

    $ALLO
    $APLT
    $ATXI
    $CGTX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Voyager Therapeutics Inc.

    SCHEDULE 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

    3/27/26 2:17:17 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Dermata Therapeutics Inc.

    10-K - Dermata Therapeutics, Inc. (0001853816) (Filer)

    3/26/26 5:17:33 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dermata Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)

    3/26/26 5:16:14 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLO
    $APLT
    $ATXI
    $CGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Allogene upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Allogene from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    1/9/26 8:23:08 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Applied Therapeutics downgraded by Robert W. Baird

    Robert W. Baird downgraded Applied Therapeutics from Outperform to Neutral

    12/12/25 9:22:39 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Applied Therapeutics from Outperform to Market Perform and set a new price target of $1.00

    12/3/25 8:27:30 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLO
    $APLT
    $ATXI
    $CGTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant

    NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has received European Patent EP3752831, related to contextualizing fingerprint chemical analysis with fingerprint deposition volume. The grant marks the Company's eighth European patent, further enhancing intellectual property rights around its fingerprint sweat drug testing technology. The newly granted patent protects a key advancement in how the Company's technology analyzes substances detected in fingerprint sweat by correlating chemical findings with the volum

    3/26/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

    -Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Management will host a live webcast conference call at 8:30 a.m. ET to review these financial results and provide an update on clinical development plans for zervimesine (CT1812) in dementia with Lewy

    3/26/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

    PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), plans to release financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 26, 2026 before the market open. Management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating results and provide a business update.    Conference Call InformationTo participate in the conference call, dial (800) 445-7795 (U.S.) or (785) 424-1699 (international) and provide conference ID number CGTXQ4. The webc

    3/23/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    $APLT
    $ATXI
    $CGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Boyages Steven Constantine

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/20/26 5:00:35 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Hurd Jonathan Scott

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/20/26 5:00:31 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Sakiris Spiro Kevin

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/20/26 5:00:32 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $ALLO
    $APLT
    $ATXI
    $CGTX
    Leadership Updates

    Live Leadership Updates

    View All

    Applied Therapeutics Reports Third Quarter 2025 Financial Results

    –   Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes –   Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the treatment of Classic Galactosemia –   New data on govorestat for the treatment of PMM2-CDG published in JIMD and presented at the 2025 ASHG Annual Meeting –   Announces Board of Directors Leadership Transition NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today reported financial results for the third quarter ended September 30

    11/13/25 7:00:00 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exagen Inc. Appoints Chas McKhann to Board of Directors

    CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholde

    7/17/25 4:05:00 PM ET
    $XGN
    Medical Specialities
    Health Care

    Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

    CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune resea

    6/23/25 9:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    $ALLO
    $APLT
    $ATXI
    $CGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Exagen Inc.

    SC 13G/A - EXAGEN INC. (0001274737) (Subject)

    12/12/24 5:00:54 PM ET
    $XGN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $ALLO
    $APLT
    $ATXI
    $CGTX
    Financials

    Live finance-specific insights

    View All

    Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

    -Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Management will host a live webcast conference call at 8:30 a.m. ET to review these financial results and provide an update on clinical development plans for zervimesine (CT1812) in dementia with Lewy

    3/26/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

    PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), plans to release financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 26, 2026 before the market open. Management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating results and provide a business update.    Conference Call InformationTo participate in the conference call, dial (800) 445-7795 (U.S.) or (785) 424-1699 (international) and provide conference ID number CGTXQ4. The webc

    3/23/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

    Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided 1L Consolidation Treatment in Both Academic and Community Cancer Centers, and Advances a Broader Delivery of CAR T at Biologic-Like ScaleInterim Futility Analysis Evaluating MRD Clearance and Early Safety Results Planned for April 2026 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID) ALLO-329, a Dual CD19/CD70 CAR, Harnesses the Dagger® Technology to Reduce or Eliminate LymphodepletionRESOLUTION Basket Trial in Rheumatology Enrolling in the Dose Escalation Phase with Proof-of-Co

    3/12/26 4:02:00 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care